Skip to main content

Table 5 Prognostic index adjusted Cox models

From: Relationship between WBRT total dose, intracranial tumor control, and overall survival in NSCLC patients with brain metastases - a single-center retrospective analysis

Prognostic
Index
  OSUnivariatePrognostic Index & RT modalitya adjusted
n(%)MTSpbHRpcHRpcWBRT (Gy)HRpc
RPA class
 I18(3)14.10.0390.4350.0320.5450.122none1.000ref.
 II387(65)9.5 0.8390.0940.7030.001< 301.4120.120
 III190(32)8.7 1.000ref.1.000ref.30–390.9690.861
         ≥400.7250.019
         ≥40 vs. 30–390.8200.270
Lung-GPA score
  0–1.0217(36)8.30.0011.000ref.1.000ref.none1.000ref.
 1.5–2.0244(41)8.5 0.9350.5280.9100.387< 301.4970.072
 2.5–3.0117(20)13.0 0.6150.0010.5800.00030–390.9190.644
 3.5–4.017(3)17.2 0.4780.0310.5110.051≥400.7310.023
         ≥40 vs. 30–390.8640.409
Lung-molGPA score
  0–1.0169(28)7.00.0001.000ref.1.000ref.none1.000ref.
 1.5–2.0289(49)8.9 0.7150.0020.6290.000< 301.6730.026
 2.5–3.0126(21)12.7 0.5210.0000.4530.00030–390.8900.516
 3.5–4.011(2)25.0 0.2590.0080.1860.001≥400.6970.009
         ≥40 vs. 30–390.8450.342
  1. OS overall survival; RT radiotherapy; MTS median survival time in months; WBRT whole brain radiotherapy; HR hazard ratio; ref. reference; RPA the recursive partitioning analysis; GPA the graded prognostic assessment; Lung-GPA the lung cancer-specific GPA; Lung-molGPA the lung cancer-specific GPA using molecular markers.
  2. aRT modalities included WBRT, local/boost RT and SRT.
  3. bfrom the log-rank test.
  4. cfrom the Cox model analysis